Neuropathix Inc logo

NPTX - Neuropathix Inc Share Price

$0.059 0.0  0.0%

Last Trade - 18/10/21

Micro Cap
Market Cap £3.78m
Enterprise Value £4.99m
Revenue £23.3k
Position in Universe 6955th / 7243
Unlock NPTX Revenue
Relative Strength (%)
1m +39.7%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -92.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.15 0.035 0.001 0.17 0.13 0.000 -100.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2021, NeuropathixInc revenues increased from $0K to $32K. Net loss decreased12% to $2.1M. Revenues reflect an increase in demand forthe Company's products and services due to favorable marketconditions. Lower net loss reflects Interest Expensedecrease of 60% to $245K (expense). Basic Earnings perShare excluding Extraordinary Items increased from -$0.03to -$0.02.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


NPTX Revenue Unlock NPTX Revenue

Net Income

NPTX Net Income Unlock NPTX Revenue

Normalised EPS

NPTX Normalised EPS Unlock NPTX Revenue

PE Ratio Range

NPTX PE Ratio Range Unlock NPTX Revenue

Dividend Yield Range

NPTX Dividend Yield Range Unlock NPTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NPTX EPS Forecasts Unlock NPTX Revenue
Profile Summary

Neuropathix, Inc., formerly Kannalife, Inc., is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics from synthetic cannabinoid derivatives platform for a range of inflammatory and neuropathic pain related diseases. The Company's drug candidates include KLS-13019 and KLS-13023. Its product, KLS-13019, is a non-opioid solution for chronic and neuropathic pain to prevent and reverse neuropathic pain in the model to treat chemotherapy-induced peripheral neuropathy (CIPN). KLS-13023 is a drug candidate that includes a synthetic cannabidiol (CBD) formulated in a gel capsule designed to use in humans. It also focuses on treating oxidative stress-related diseases, including overt hepatic encephalopathy (OHE), chronic pain from neuropathies, and neurodegenerative disease, including chronic traumatic encephalopathy (CTE) and mild traumatic brain injury (mTBI). It owns neuroprotective and anticonvulsant small-molecule drug technology.

Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated March 25, 2013
Public Since September 12, 2016
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Pink Sheets on Nasdaq
Shares in Issue 87,978,445
Free Float (0.0%)
Eligible for
× ISAs
NPTX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for NPTX
Upcoming Events for NPTX
Frequently Asked Questions for Neuropathix Inc
What is the Neuropathix Inc share price?

As of 18/10/21, shares in Neuropathix Inc are trading at $0.059, giving the company a market capitalisation of £3.78m. This share price information is delayed by 15 minutes.

How has the Neuropathix Inc share price performed this year?

Shares in Neuropathix Inc are currently trading at $0.059 and the price has moved by -88.19% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Neuropathix Inc price has moved by -90.59% over the past year.

What are the analyst and broker recommendations for Neuropathix Inc?

There are no analysts currently covering Neuropathix Inc.

When will Neuropathix Inc next release its financial results?

Neuropathix Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Neuropathix Inc dividend yield?

Neuropathix Inc does not currently pay a dividend.

Does Neuropathix Inc pay a dividend?

Neuropathix Inc does not currently pay a dividend.

When does Neuropathix Inc next pay dividends?

Neuropathix Inc does not currently pay a dividend.

How do I buy Neuropathix Inc shares?

To buy shares in Neuropathix Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Neuropathix Inc?

Shares in Neuropathix Inc are currently trading at $0.059, giving the company a market capitalisation of £3.78m.

Where are Neuropathix Inc shares listed? Where are Neuropathix Inc shares listed?

Here are the trading details for Neuropathix Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: NPTX
What kind of share is Neuropathix Inc?

Based on an overall assessment of its quality, value and momentum, Neuropathix Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Neuropathix Inc share price forecast 2021?

We were not able to load any forecast data for Neuropathix Inc.

How can I tell whether the Neuropathix Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuropathix Inc. Over the past six months, the relative strength of its shares against the market has been -56.38%. At the current price of $0.059, shares in Neuropathix Inc are trading at -55.81% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Neuropathix Inc PE Ratio?

We were not able to find PE ratio data for Neuropathix Inc.

Who are the key directors of Neuropathix Inc?

We were unable to find the directors for Neuropathix Inc.

Who are the major shareholders of Neuropathix Inc?

Here are the top five shareholders of Neuropathix Inc based on the size of their shareholding:

Petkanas Dean Individual Investor
Percentage owned: 26.13% (23.0m shares)
Medical Marijuana Inc Corporation
Percentage owned: 23.12% (20.3m shares)
Kettner Investments, L.L.C. Corporation
Percentage owned: 7.75% (6.82m shares)
Kikis (Thomas Evangelos) Individual Investor
Percentage owned: 6.2% (5.45m shares)
Corrao (Mark Joseph) Individual Investor
Percentage owned: 1.76% (1.55m shares)
Similar to NPTX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.